Hydrocephalus is a chronic neurological condition wherein there is an excess accumulation of cerebrospinal fluid in the brain. Credit: Marcin Janiec / Shutterstock.com.

Neurological device company Anuncia Medical has commercially introduced the second-generation device, ReFlow Mini Flusher in the US.

Approved by the US Food and Drug Administration (FDA), the device is intended for the treatment of hydrocephalus or similar conditions at several neurosurgical centres across the country.

Go deeper with GlobalData

Data Insights

The gold standard of business intelligence.

Find out more

Related Company Profiles

View all

A chronic neurological condition, hydrocephalus occurs due to an excess accumulation of cerebrospinal fluid (CSF) in the brain.

With a reduced size and profile, the new device supports a wider range of hydrocephalus patients, from infants to older adults.

A patented device, the ReFlow Mini Flusher can be used with any shunt system brand.

Its unique design allows it to flush the CSF back into the ventricular catheter, thereby helping to maintain, restore or increase hydrocephalus shunt flow, just with the push of the soft dome of the flusher placed beneath the patient’s scalp.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

Anuncia Medical CEO and president Elsa Chi Abruzzo said: “Today is an important milestone as the company begins to meet the needs of neurosurgeons who have been waiting since the start of the Covid pandemic for our ReFlow Mini Gen 2 device to become available.”

According to the data published in the Journal of Pediatric Neurosurgery on the first-generation ReFlow device, its use may cut down the high rate of shunt malfunctions because of catheter occlusions and related repeat revision brain surgeries.

ReFlow has been granted breakthrough designation by the FDA and the company plans to further investigate it in future clinical studies.